Tradestie Institutional Equity Comparison Engine

NMAD vs PALI โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PALI Overall Edge

PALI Captures Institutional Edge (2โ€“1 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Palisade Bio, Inc. Common Stock (PALI) driven by superior Valuation, Growth & Margin while NMAD counters with relative strength in Momentum & Technical. Fundamentally, NMAD trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus PALI at N/M Forward P/E and -9625.4% operating margin (+0.0% YoY). In options structure, NMAD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against PALI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner PALI
NMAD N/M vs PALI N/M Fwd P/E
Growth & Margin Winner PALI
Op Margin N/A vs -9625.4% ยท YoY N/A vs +0.0%
Momentum & Technical Winner NMAD
1Y -65.1% vs -61.3% ยท 52W Pos 8% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
NMAD US Equity
NMAD
Institutional Equity
$2.56
+13.53% 1D
Market Cap N/A
1M Return -28.89%
1Y Return -65.12%
Forward P/E N/M
Unified AI Score
47.9 / 100 HOLD
Tech 43.0 Fund 49.0 Flow 50.0 Mom 70.0
PALI NASDAQ
Palisade Bio, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.84
-9.24% 1D
Market Cap $166.1M
1M Return -37.79%
1Y Return -61.29%
Forward P/E N/M
Unified AI Score
39.3 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NMAD -65.12% PALI -61.29% Spread: +6.29 pp (PALI Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NMAD TTM Op. Margin: N/A PALI TTM Op. Margin: -9625.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NMAD vs PALI. Trailing 12-month operating profitability (NMAD N/A vs PALI -9625.4%) and valuation multiples (NMAD N/M vs PALI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NMAD (2) vs PALI (7)
Institutional Metric NMAD PALI Criterion Row Winner
Market Capitalization Scale N/A $166.1M Larger Scale PALI
Trailing P/E Ratio Valuation N/M 1.0x Lower Multiple PALI
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth PALI
Operating Margin (TTM) Profitability N/A -9625.4% Higher Margin PALI
Net Profit Margin Profitability N/A 0.0% Higher Margin PALI
Return on Equity (ROE) Capital Efficiency N/A -75.6% Higher ROE PALI
52-Week Range Position Momentum 8% ($2โ€“$8) 0% ($1โ€“$3) Stronger Trend NMAD
Beta / 30D Volatility Risk Regime 0.52ฮฒ ยท 173% Vol 1.44ฮฒ ยท 70% Vol Lower Realized Risk PALI
Unified Institutional Score Composite Signal 47.9 / 100 (HOLD) 39.3 / 100 (SELL) Higher Composite NMAD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NMAD vs PALI Buy Guide
NMAD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live NMAD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PALI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live PALI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NMAD nor PALI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.